Latest news with #litigation
Business Upturn
a day ago
- Business
- Business Upturn
INVESTOR DEADLINE: Robbins Geller Announces that Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co. , No. 25-cv-05322 (D.N.J.) – seeks to represent purchasers or acquirers of Organon & Co. (NYSE: OGN) securities and charges Organon as well as certain of Organon's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Organon class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Organon class action lawsuit must be filed with the court no later than Tuesday, July 22, 2025. CASE ALLEGATIONS: Organon develops and delivers health solutions through prescription therapies and medical devices. The Organon class action lawsuit alleges that defendants throughout the class period made false and/or misleading statements and/or failed to disclose that: (i) defendants concealed material information pertaining to Organon's capital allocation priorities, particularly the future of the quarterly dividend payout; (ii) in truth, Organon's optimistic reports of the dividend payout as Organon's 'number one priority' were offset by Organon's newly implemented debt reduction strategy, thus, leading to a drastic decrease – over 70% – of the quarterly dividend; and (iii) Organon planned to prioritize debt reduction following Organon's acquisition of Dermavant Sciences Ltd. The Organon class action lawsuit further alleges that on May 1, 2025, Organon reported first quarter 2025 financial results and announced that management reset Organon's dividend payout from $0.28 to $0.02. On this news, the price of Organon stock fell more than 27%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Organon securities during the class period to seek appointment as lead plaintiff in the Organon class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Organon class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Organon class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Organon class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
Business Wire
a day ago
- Business
- Business Wire
Rosen Law Firm Urges Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the 'Class Period'). Sarepta is a commercial-stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Misled Investors Regarding its Business Operations. According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (3) the severity of adverse events from ELEVIDYS treatment would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (4) as a result of the foregoing, Defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Sarepta Therapeutics, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 25, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
India Gazette
2 days ago
- Business
- India Gazette
Mansukh Mandaviya chairs 196th meeting of Employees' State Insurance Corporation in Shimla
Shimla (Himachal Pradesh) [India], June 27 (ANI) Union Minister for Labour and Employment and Youth Affairs and Sports, Mansukh Mandaviya, chaired the 196th meeting of the Employees' State Insurance Corporation (ESIC) at Shimla, Himachal Pradesh on Friday. According to an official release, the Corporation deliberated and approved several key agenda items aimed at enhancing ESIC's operational reach, infrastructure, and healthcare delivery. The Employees' State Insurance Corporation has approved the re-launch of SPREE (Scheme to Promote Registration of Employers, Employees) with the objective of expanding ESI coverage across the country. Originally introduced in 2016, the scheme successfully facilitated the registration of over 88,000 employers and 1.02 crore employees. The renewed SPREE will be open from July 1 to December 31, offering a one-time opportunity for unregistered employers and left-out workers--including contractual and temporary staff--to enroll under the ESI Act. Under the scheme, employers registering during this period will be treated as covered from the date of registration or as declared by them, while newly registered employees will be covered from their respective dates of registration. By focusing on voluntary compliance rather than penalization, the scheme will seek to ease the litigation burden, encourage formal registration, and foster improved engagement and goodwill among stakeholders. The ESI Corporation has approved the Amnesty Scheme - 2025, a one-time dispute resolution window from October 1 to September 30, 2026 aimed at reducing litigation and promoting compliance under the ESI Act. For the first time, disputes along with cases involving damages and interest regarding coverage are included. Regional Directors have been empowered to withdraw cases where contributions and interest have been paid, and also to withdraw cases filed against insured persons over five years ago where no notices were issued. The scheme aims to reduce the number of litigations by providing a mechanism for the resolution of disputes outside the court, offering employers an opportunity to come forward for a mutual settlement to promote ease of doing business, and earn the goodwill of all stakeholders. ESI Corporation has decided to simplify its damages framework by replacing the earlier framework of graded rates in favour of straightforward fixed rate. Further, the maximum rate of damage in the earlier framework was 25 per cent per annum, which has now been reduced to 1 per cent for every month on the amount payable by the employer. This change will promote compliance, minimize disputes and foster a more conducive regulatory environment. The Corporation approved the proposal to delegate powers to the Director General, ESIC, to grant relaxation in submission of applications beyond the 12-month limit from the date of job loss under RGSKY on case-to-case basis. The Employees' State Insurance Corporation has considered and approved the Revised AYUSH Policy of ESIC. This policy focuses on integrating traditional systems of medicine such as Ayurveda, Yoga, Unani, Siddha, and Homeopathy into the ESIC healthcare network. The aim is to promote holistic, preventive, and wellness-oriented healthcare. It marks a strategic move to enhance the overall medical services provided to ESIC beneficiaries. The Corporation has approved the engagement of Yoga therapists and Panchakarma technicians/attendants in ESIC hospitals. The Corporation approved a pilot project to improve healthcare access for ESI beneficiaries by partnering with charitable hospitals in underserved areas. These hospitals will provide comprehensive services--from OPD to emergency care--ensuring affordable, quality treatment while advancing ESIC's mission of social security and welfare. The pilot will be initiated in a few districts of the country. The 196th meeting of the ESI Corporation was attended by Dola Sen, Member of Parliament (Rajya Sabha), NK Premachandra, Member of Parliament (Lok Sabha), Ashok Kumar Singh, Director General, ESIC, Principal Secretaries/Secretaries of the state governments, representatives of employers, employees and senior officers from the Ministry of Labour and Employment, Govt of India and ESIC. (ANI)
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
ESIC approves one-time amnesty scheme to cut litigation, boost ESI
In a bid to reduce litigation and promote compliance under the Employees' State Insurance (ESI) Act, 1948, the ESI Corporation (ESIC) on Friday approved a one-time amnesty scheme—applicable from October 1, 2025. 'The scheme aims to reduce the number of litigations by providing a mechanism for the resolution of disputes outside the court, offering employers an opportunity to come forward for a mutual settlement to promote ease of doing business, and earn the goodwill of all stakeholders,' the labour ministry said in a statement after the meeting of the apex decision-making body of the social security organisation. The scheme will remain applicable until September 30, 2026. Under the scheme, regional directors have been empowered to withdraw cases where contributions and interest have been paid, and also to withdraw cases filed against insured persons over five years ago where no notices were issued. For the first time, disputes involving damages and interest related to coverage are also included. In addition, the ESIC has approved the re-launch of SPREE (Scheme to Promote Registration of Employers/Employees) with the objective of expanding ESI coverage across the country. Introduced in 2016, the scheme successfully facilitated the registration of over 88,000 employers and 10.2 million employees. The renewed SPREE will be open from July 1 to December 31, 2025, offering a one-time opportunity for unregistered employers and left-out workers—including contractual and temporary staff—to enrol under the ESI Act. Employers registering during this period will be treated as covered from the date of registration or as declared by them, while newly registered employees will be covered from their respective dates of registration. 'By focusing on voluntary compliance rather than penalisation, the scheme will seek to ease the litigation burden, encourage formal registration, and foster improved engagement and goodwill among stakeholders,' the labour ministry statement said.
Bloomberg
2 days ago
- Business
- Bloomberg
AI Copyright Rulings, Trump Antitrust, PBMs: Votes and Verdicts
Key court rulings on June 23 and 25 in cases against Anthropic and Meta over the use of copyrighted material in large language models are among the catalysts Bloomberg Intelligence litigation and policy analysts are watching this week. The decisions are also relevant for Google, Microsoft, the New York Times, OpenAI and more. The team also discussed the outlook for antitrust enforcement of M&A under President Trump, with ramifications for several pending deals, including Dick's Sporting Goods-Foot Locker, Charter-Cox and Google-Wiz. CVS and Cigna Express Scripts are challenging an Arkansas law that would ban operators of pharmacy benefit managers from holding pharmacy licenses. Finally, we discussed the outlook for FCC de-regulation, including to remove broadcast caps, with implications for Nexstar, Sinclair and Tegna.
